Perez, E A <br/><br/>
Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.  [electronic resource] 

 -  Clinical breast cancer  Sep 2000 
 - S52-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1526-8209 
<br/><br/><label>Standard No.: </label>10.3816/cbc.2000.s.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Clinical Trials, Phase III as Topic<br/>Cyclophosphamide--administration & dosage<br/>Drug Administration Schedule<br/>Epirubicin--administration & dosage<br/>Female<br/>Humans<br/>Research Design<br/>Survival Analysis<br/>Taxoids--administration & dosage